1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. News
  7. Summary
    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Real-time Estimate Cboe Europe  -  05/25 10:59:45 am EDT
747.90 DKK   +0.15%
05/24NOVO NORDISK : Deutsche Bank remains its Buy rating
MD
05/23Novo Nordisk A/S – Share repurchase programme
GL
05/20European ADRs Move Sharply Higher in Friday Trading
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novo Nordisk announces settlement of securities lawsuit in Denmark

01/14/2022 | 11:15am EDT

Bagsværd, Denmark, 14 January 2022Novo Nordisk today announced that the company has settled a securities lawsuit in Denmark filed in August 2019. The settlement contains no admission of liability, wrongdoing or responsibility by Novo Nordisk and no payment will be made by Novo Nordisk to the plaintiffs.

The lawsuit was filed by a number of shareholders and alleged that Novo Nordisk had made misleading statements and did not make appropriate disclosures regarding its sales of insulin products in the US. The original claim was for a total amount of DKK 11,785,192,218.

About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).

Further information

Media:  
Mette Kruse Danielsen+45 3079 3883mkd@novonordisk.com
Michael Bachner (US)+1 609 664 7308mzyb@novonordisk.com
   
Investors:  
Daniel Muusmann Bohsen+45 3075 2175dabo@novonordisk.com
Ann Søndermølle Rendbæk+45 3075 2253arnd@novonordisk.com
David Heiberg Landsted+45 3077 6915dhel@novonordisk.com
Mark Joseph Root (US)+1 848 213 3219mjhr@novonordisk.com

Company announcement No 2 /2022

Attachment

  • PR220114_Settlement_Danish_lawsuit

© OMX, source GlobeNewswire - EU Press Releases

All news about NOVO NORDISK A/S
05/24NOVO NORDISK : Deutsche Bank remains its Buy rating
MD
05/23Novo Nordisk A/S – Share repurchase programme
GL
05/20European ADRs Move Sharply Higher in Friday Trading
MT
05/20NOVO NORDISK : Berenberg remains Neutral
MD
05/16European ADRs Move Higher in Monday Trading
MT
05/16NOVO NORDISK A/S : Share repurchase programme
GL
05/16NOVO NORDISK A/S : Share repurchase programme
GL
05/13U.S. FDA approves Eli Lilly's treatment for type 2 diabetes
RE
05/12NOVO NORDISK : Barclays gives a Buy rating
MD
05/11NOVO NORDISK A/S : Trading in Novo Nordisk shares by board members, executives and associa..
GL
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Financials
Sales 2022 166 B 23 853 M 23 853 M
Net income 2022 52 875 M 7 589 M 7 589 M
Net cash 2022 4 087 M 587 M 587 M
P/E ratio 2022 31,8x
Yield 2022 1,54%
Capitalization 1 677 B 241 B 241 B
EV / Sales 2022 10,1x
EV / Sales 2023 8,88x
Nbr of Employees 49 295
Free-Float 69,6%
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 746,80 DKK
Average target price 791,88 DKK
Spread / Average Target 6,04%
EPS Revisions
Managers and Directors
Lars Fruergaard J°rgensen President & Chief Executive Officer
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Helge Lund Chairman
Henrik Ehlers Wulff Senior Vice President-Diabetes API
Stephen Gough Global Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVO NORDISK A/S1.61%244 637
JOHNSON & JOHNSON6.04%477 336
PFIZER, INC.-9.55%299 678
ROCHE HOLDING AG-12.57%281 309
ELI LILLY AND COMPANY10.77%275 413
ABBVIE INC.10.13%263 494